Generic Version of Adcirca to be Launched in US Under Brand Name ALYQ for PAH - Pulmonary Hypertension News

Generic Version of Adcirca to be Launched in US Under Brand Name ALYQ for PAH  Pulmonary Hypertension News

Teva is launching a generic version of Adcirca (tadalafil) in the United States under the brand name ALYQ for the treatment of PAH.



Comments

Post a Comment

Popular posts from this blog

4 Symptoms of Stress You Should Never Ignore - AARP

Image
Vadym Pastukh/Getty Images Wins and medals aren't the only things grabbing attention at this year's Olympic games in Tokyo: Mental health awareness is also in the spotlight, after U.S. star gymnast Simone Biles' decision to withdraw from some events in order to focus on her emotional well-being.  Olympians or not, we're all susceptible to stress, whether from job or family pressures or obligations like caregiving. Here are the physical and mental signs that experts say could signal trouble.   1. Insomnia and difficulty sleeping  Can't fall or stay asleep? Insomnia is a class...
Read more

Dyspnea (Shortness of Breath): Causes, Symptoms & Treatment - my.clevelandclinic.org

Image
Overview Shortness of breath (dyspnea) is most commonly caused by heart or lung conditions. Other causes include anemia, anxiety, lack of exercise or living with obesity. What is dyspnea (shortness of breath)? Dyspnea (pronounced "DISP-nee-uh") is the word healthcare providers use for feeling short of breath. You might describe it as not being able to get enough air ("air hunger"), chest tightness or working harder to breathe. Shortness of breath is often a symptom of heart and lung problems. But it can also be a sign of other conditions like asthma, allergies or anxiety. Intense exercise or having a cold can also make you feel breathless. What are paroxysmal nocturnal dyspnea (PND) and sighing dyspnea? Paroxysmal nocturnal dyspnea (PND) is a feeling like you can't breathe an hour or two after falling asleep. Sighing dyspnea is when you sigh a lot after taking deep breaths in to try to relieve the feeling of dyspnea. What is the differ...
Read more

Top pulmonology news from July: FDA updates, antibiotics in cystic fibrosis, treatment of COPD exacerbations - Healio

Image
Top pulmonology news from July: FDA updates, antibiotics in cystic fibrosis, treatment of COPD exacerbations - Healio Top pulmonology news from July: FDA updates, antibiotics in cystic fibrosis, treatment of COPD exacerbations - Healio Posted: 02 Aug 2019 06:01 AM PDT Healio Pulmonology has you covered. The Editors have compiled a list of the most-popular articles posted on Healio Pulmonology in July. See below for links to a study on reducing antibiotic use for COPD exacerbations, the outcome of an FDA advisory committee meeting on nintedanib for a rare form of interstitial lung disease, updates on treatment of respiratory infections in patients with cystic fibrosis and more. C-reactive protein testing safely reduces antibiotic use for COPD exacerbations The use of point-of-care testing for C-reactive protein to guide treatment lessened the use of antibiotics for COPD exacerbations without worsening clinical outcomes, according to a...
Read more